Extensive preclinical validation of combined RMC-4550 and LY3214996 supports clinical investigation for KRAS mutant pancreatic cancer
Katrin J. Frank, Antonio Mulero‐Sánchez, Alexandra Berninger, Laura Ruíz-Cañas, Astrid Bosma, Kıvanç Görgülü, Nan Wu, Kalliope N. Diakopoulos, Ezgi Kaya-Aksoy, Dietrich Alexander Ruess, Derya Kabacaoğlu, Fränze Schmidt, Larissa Kohlmann, Olaf van Tellingen, Bram Thijssen, Marieke van de Ven, Natalie Proost, Susanne Kossatz, Wolfgang Weber, Bruno Sáinz, René Bernards, Hana Algül, Marina Lesina, Sara Mainardi
Abstract
F-fluorodeoxyglucose (FDG) positron emission tomography (PET) can be used to assess early drug responses in animal models. Based on these results, we will investigate this drug combination in the SHP2 and ERK inhibition in pancreatic cancer (SHERPA; ClinicalTrials.gov: NCT04916236) clinical trial, enrolling patients with KRAS-mutant PDAC.